Immunoassay Large Particle Markers for Rapid Point-of-Care Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunoassays require large sample volumes and lengthy analysis times, making them unsuitable for point-of-care settings like emergency departments and ambulances, especially when detecting biomarkers at low concentrations, such as NT-proBNP for heart failure diagnosis, which demands high sensitivity and speed.
Innovation Solution
The use of capture moieties not specific for the same epitope in combination with large particle markers, which enhances the binding efficiency and sensitivity of the assay by compensating for the reduced rotational freedom of the marker-target complex, allowing for faster and more accurate detection of small analytes like NT-proBNP.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If large particle markers are used to enhance detection sensitivity, then measurement precision is improved, but the rotational freedom of the marker-target complex is reduced, worsening binding efficiency
Solution Approach 1:
The patent introduces a flexible linker as an intermediary component between the detection antibody and the large particle marker. This linker acts as a molecular bridge that transmits the binding force while accommodating the rotational constraints imposed by the large marker size, thereby maintaining binding efficiency despite the use of enhanced sensitivity markers
Solution Approach 2:
The patent modifies the physical parameters of the detection system by using large particle markers (with specific size ranges) and compensating for their rotational constraints through the flexible linker design. This parameter change increases the signal-to-noise ratio for detection while the linker maintains the functional binding capability
2Measurement precision
If conventional immunoassay methods are used, then detection of biomarkers is achieved, but analysis time is extended to 15 minutes or more, reducing productivity
Solution Approach 1:
The patent employs pre-functionalized large particle markers that are prepared in advance with detection antibodies attached. This preliminary preparation eliminates time-consuming in-lab conjugation steps during the actual assay, enabling rapid deployment and reducing total analysis time to under 5 minutes while maintaining detection sensitivity
Solution Approach 2:
The patent utilizes the dynamic flexibility of the linker to enable rapid binding kinetics. The flexible connection allows the detection antibody to quickly adjust and bind to the target antigen even when attached to a large marker, accelerating the assay process without sacrificing measurement precision
3Measurement precision
If conventional immunoassay methods are used, then biomarker detection is performed, but large sample volumes are required, increasing device complexity
Solution Approach 1:
The patent concentrates the detection capability at the local level by attaching detection antibodies directly to large particle markers that provide enhanced signal amplification. This local enhancement of detection sensitivity allows the use of smaller sample volumes, as the signal per unit volume is significantly increased compared to conventional methods
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables rapid and sensitive detection of small analytes, reducing assay time to less than 5 minutes with sample volumes as low as 1-30 μL, facilitating quick lab-quality results in point-of-care settings using a handheld device.
Implementation Method 1
The detectable marker to which the epitope-specific detection moiety is bound is a large particle marker having a particle size of ≥50 nm and ≤5000 nm
Data Source
AI summary
An immunoassay for the detection of an analyte in a sample includes a plurality of moieties capable of binding to the analyte. Capture moieties, which are not specific for the same epitope, are bound to a solid substrate, and at least one epitope-specific detection moiety is bound to a detectable marker. The detectable marker is a large particle marker having a particle size of ≥50 nm and ≤5000 nm.